Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
MEDROXYPROGESTERONE ACETATE
PFIZER CANADA ULC
G03DA02
MEDROXYPROGESTERONE
100MG
TABLET
MEDROXYPROGESTERONE ACETATE 100MG
ORAL
100
Prescription
PROGESTINS
Active ingredient group (AIG) number: 0106339007; AHFS:
CANCELLED POST MARKET
2012-02-13
_ _ _PROVERA / PROVERA-PAK (medroxyprogesterone acetate) Product Monograph _ _Page 1 of 42_ PRODUCT MONOGRAPH PR PROVERA* (medroxyprogesterone acetate USP) 2.5 mg, 5 mg, 10 mg and 100 mg tablets and PR PROVERA-PAK* (medroxyprogesterone acetate USP) 5 mg and 10 mg tablets PROGESTIN Pfizer Canada Inc. 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 DATE OF REVISION: December 9, 2009 SUBMISSION CONTROL NO: 133050 * TM Pharmacia & Upjohn Company LLC Pfizer Canada Inc., Licensee © Pfizer Canada Inc. 2009 _PROVERA / PROVERA-PAK (medroxyprogesterone acetate) Product Monograph _ _Page 2 of 42_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS..................................................................................5 ADVERSE REACTIONS..................................................................................................14 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION..............................................................................18 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................22 STORAGE AND STABILITY..........................................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................25 PART II: SCIENTIFIC INFORMATION ...............................................................................27 PHARMACEUTICAL INFORMATION..........................................................................27 CLINICAL TRIAL Baca dokumen lengkap